This page exists because you've done your research. Here is the same evidence that informs Dr. Baley's clinical decisions — with sources, so you can verify everything yourself.
BII is not a formal medical diagnosis — yet. It is a recognized pattern of systemic symptoms reported by thousands of women with breast implants. The FDA, ASPS, and ISAPS have all acknowledged its existence. The debate is no longer whether it is real, but how it works.
Women with breast implants have reported a consistent cluster of symptoms: chronic fatigue, cognitive impairment (often called "brain fog"), joint and muscle pain, hair loss, skin rashes, and autoimmune-like responses. These symptoms frequently improve or resolve after explant surgery.
The FDA has formally acknowledged BII, adding it to required patient information since 2020. The ASPS has published guidance recognizing BII as a clinical concern. ISAPS has called for more research while affirming that patients with these symptoms deserve serious medical attention — not dismissal.
Researchers have proposed several pathways that may explain why some patients develop systemic symptoms. These are not mutually exclusive — more than one mechanism may be active in the same patient.
The immune system recognizes the implant shell as non-self and mounts a chronic inflammatory response that can become systemic over time.
Autoimmune/inflammatory syndrome induced by adjuvants. Silicone acts as an immune adjuvant, triggering autoimmune pathways in genetically predisposed patients.
Bacteria colonize the implant surface, forming a biofilm that triggers persistent low-grade infection and chronic immune activation undetectable by standard cultures.
Microscopic silicone molecules migrate through intact implant shells and accumulate in lymph nodes, liver, and other organs — even without rupture.
HLA genotypes and specific polymorphisms may determine which patients develop systemic reactions. This could explain why some women have implants for decades without symptoms while others react within months.
A 2025 study published in Scientific Reports identified FGF-19 as a potential biomarker for BII — the first step toward a diagnostic blood test. While not yet validated for clinical use, this represents a shift from subjective symptom reporting to measurable, objective markers. The science is moving from "we believe you" to "we can measure it."
Breast Implant-Associated Anaplastic Large Cell Lymphoma is a rare cancer of the immune system — not breast cancer — that develops in the capsule surrounding a breast implant. It is treatable when caught early, but it has caused documented deaths.
BIA-ALCL is not random. It is strongly correlated with implant surface type. The overwhelming majority of cases involve macro-textured implants — specifically the Allergan Biocell surface, which was recalled by the FDA in July 2019.
Median onset is 9 years after implantation. The most common presentation is late-onset seroma — fluid accumulation around the implant that develops years after surgery, often without pain. Early detection and complete surgical removal (capsulectomy) results in excellent outcomes.
| Surface type | Risk estimate | Examples | Notes |
|---|---|---|---|
| Smooth | Extremely rare / near zero | Most US-market implants | Fewest reported cases |
| Nanotextured | Near zero | Motiva SilkSurface | FDA classifies as essentially smooth |
| Microtextured | ~1 in 80,000 | Various manufacturers | Low but nonzero risk |
| Macro-textured (salt-loss) | 1 in 2,000 – 1 in 86,000 | Allergan Biocell (recalled) | Highest risk. Recalled by FDA 2019 |
| Polyurethane | ~1 in 200,000+ | Polytech Mesmo | Lowest recorded among textured devices |
In October 2019, the FDA mandated a boxed warning — its most serious regulatory category — on all breast implants sold in the United States. This was not a recommendation. It was a requirement.
The boxed warning applies to every breast implant, regardless of manufacturer, fill type, or surface texture. It states that breast implants are not lifetime devices and carry risks including BIA-ALCL, breast implant illness, capsular contracture, rupture, and the need for additional surgery.
Simultaneously, the FDA mandated a Patient Decision Checklist — a document that must be reviewed and signed before any breast implant surgery. For the first time, patients must be informed, in writing, of specific risks that were previously communicated inconsistently or not at all.
The surface of an implant determines how the body responds to it. The FDA now classifies implant surfaces into five categories, each with distinct biological behavior and risk profiles.
No surface texture. Forms a thin, sliding capsule. Most common in the US market. Lowest BIA-ALCL risk, but higher rates of implant rotation and displacement.
Surface roughness under 10 microns. Classified by the FDA as functionally equivalent to smooth. Reduces rotation risk without the biological response of true texturing.
Moderate surface roughness. Creates a thin, organized capsule that provides some tissue adherence. Lower BIA-ALCL risk than macro-textured devices.
Aggressive surface roughness created by salt-loss manufacturing. Causes a thick, disorganized inflammatory capsule. Allergan Biocell — the highest-risk device — was this category.
A polyurethane foam coating over a silicone shell. Creates a fundamentally different biological response: the foam degrades over 12-24 months, leaving a disorganized collagen capsule that prevents contracture. Biologically distinct from silicone texturing.
Not all regulatory approvals are equivalent. The rigor of the approval process determines how much safety data exists before an implant reaches your body.
There are two major regulatory frameworks for breast implants: the European Union's Medical Device Regulation (EU MDR) and the US FDA's Premarket Approval (PMA) process. Both classify breast implants as high-risk devices, but they differ significantly in how approval is granted and maintained.
In 2010, French manufacturer Poly Implant Prothese (PIP) was found to have used industrial-grade silicone instead of medical-grade silicone in hundreds of thousands of breast implants. The scandal exposed critical weaknesses in the European approval system — at the time, implants could reach the market through a less rigorous "Notified Body" process without comprehensive clinical data.
The result was a complete overhaul. The EU replaced its Medical Device Directive with the Medical Device Regulation (MDR) in 2021 — reclassifying breast implants as Class III devices (the highest risk category) and requiring clinical evidence, post-market surveillance, and unannounced audits of manufacturing facilities.
Both are rigorous, but they approach safety differently. The FDA PMA process requires clinical trial data before approval. EU MDR Class III requires conformity assessment by an independent Notified Body, plus clinical evaluation, biocompatibility testing, and ongoing post-market surveillance.
In practice: FDA approval means a device has passed a specific US clinical trial. EU MDR certification means a device meets harmonized safety standards and has ongoing oversight. Neither is objectively "better" — they are complementary frameworks that together provide the most complete safety picture.
| Criteria | FDA PMA (United States) | EU MDR Class III (Europe) |
|---|---|---|
| Device classification | Class III (highest risk) | Class III (highest risk) |
| Clinical data required | Yes — US clinical trials | Yes — clinical evaluation report |
| Post-market surveillance | Required (post-approval studies) | Required (PMCF, vigilance reporting) |
| Manufacturing audits | FDA inspections | Annual + unannounced audits |
| Traceability | UDI system | EUDAMED + UDI |
These terms are used constantly in the BII community. Here is what each one actually means in surgical practice, what goes to pathology, and why the terminology matters.
The implant and the entire surrounding capsule are removed together as a single, intact unit — without opening or rupturing the capsule during removal. The capsule acts as a sealed envelope around the implant, and both come out together.
This is the gold standard for patients with suspected BIA-ALCL, significant capsular contracture, or known implant rupture. It ensures no capsule tissue or silicone is left behind. Not every surgeon can perform true en bloc removal — it requires specific dissection technique and experience with adherent capsules.
The BII community often uses "en bloc" as shorthand for "complete and thorough removal." The medical literature uses it more precisely: the capsule must come out intact, unopened, as a single specimen. Both definitions point to the same goal — complete removal with nothing left behind.
The implant is removed first, followed by complete excision of all capsule tissue. The end result is the same — all foreign material and all capsule tissue are removed — but the capsule is not removed as a single intact unit.
Total capsulectomy is appropriate for most standard explant cases where BIA-ALCL is not suspected. All tissue is still sent to pathology for examination. The distinction from en bloc is surgical technique, not thoroughness.
The implant is removed and some — but not all — of the capsule is excised. Portions of the capsule that are thinly adherent to the chest wall or ribs may be left in place to avoid unnecessary surgical risk.
This approach is less common in explant-focused practices and is generally not recommended for patients with BII or BIA-ALCL concerns. However, in rare cases where the capsule is calcified and adherent to the ribcage, partial removal may be the safest surgical decision.
Every capsule removed in Dr. Baley's practice is sent to pathology. The pathologist examines the tissue for signs of BIA-ALCL (CD30+ cells), chronic inflammation, silicone granulomas, biofilm, calcification, and any other abnormalities.
Invasive pathological findings are rare — present in fewer than 0.2% of capsules examined. But that fraction represents real patients whose outcomes changed because their tissue was actually examined instead of being discarded in the operating room. Pathology is not optional. It is part of responsible explant surgery.
Autologous fat transfer uses your own harvested fat cells to restore breast volume after implant removal. No foreign material. No implant. Your own biology, relocated.
Fat grafting involves harvesting fat cells from a donor site — typically the abdomen, flanks, or thighs — processing them to isolate viable adipocytes, and injecting them into the breast tissue in multiple small passes. This can be performed simultaneously with explant surgery or as a staged procedure.
The technique is well-established in reconstructive and aesthetic surgery. When performed by an experienced surgeon, it produces natural-feeling results that integrate with existing breast tissue. However, honesty requires stating that graft survival is variable. Typically 60-80% of transferred fat cells survive long-term. Some patients may benefit from a second session 4-6 months later to achieve their desired volume.
If you're reading this, you've probably been researching for weeks or months. You've scrolled through forums, read studies you weren't trained to interpret, and lost sleep over what you've found. It's normal to feel afraid.
Fear is a reasonable response to uncertainty. What matters now is not eliminating fear — it's making decisions that reduce it. Here are six concrete steps, in order.
BII and BIA-ALCL are not emergencies in most cases. BII symptoms are chronic but not acutely dangerous. BIA-ALCL, when detected early, has excellent treatment outcomes. You have time to make a good decision rather than a rushed one.
Keep a written log. When symptoms started, how they've progressed, what makes them better or worse. A timeline helps any surgeon understand your situation faster and more accurately than a verbal summary.
Find out the brand, model, date of placement, and whether they are smooth or textured. This information is in your surgical records. If you can't find them, your surgeon's office or the implant manufacturer's registry can help. This is the single most important piece of information for any consultation.
Your questions will tell you if the surgeon knows what they're talking about. Ask about capsulectomy technique, pathology protocols, BIA-ALCL screening, and their explant case volume. A surgeon who focuses on breast surgery will answer without hesitation.
If the surgeon gets uncomfortable, they're not the right surgeon. Ask about complication rates, what happens if they find ALCL, whether they send every capsule to pathology, and how many explants they perform per month. The right surgeon will welcome these questions.
Any serious explant surgeon sends every capsule to pathology — without exception. If a surgeon tells you pathology isn't necessary, or that they'll "only send it if it looks suspicious," find a different surgeon. Visual inspection is not a substitute for histological analysis.
If you want to talk through what you've found, Dr. Baley offers free video consultations. No coordinators, no sales process, no obligation. Just a conversation with a surgeon who has seen what you're going through hundreds of times — and can give you honest answers about your specific situation.
No obligation. No coordinators. Just answers from a surgeon who built his entire practice around the breast.
